DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
Phase 3
Completed
- Conditions
- Cancer of the Head and Neck
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Danish Head and Neck Cancer Group
- Target Recruit Count
- 619
- Registration Number
- NCT00496652
- Locations
- 🇩🇰
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
© Copyright 2025. All Rights Reserved by MedPath